Mynzepli 40 mg/ml, Injektionslösung in einer Fertigspritze

7680706170011 CH-70617 Injektionslösung

Associated product:

MYNZEPLI 40 mg/ml sol inj ser prérempl 2 mg 1 pce

No image available

Article details

Package size
1
Selling units
1
Measure
Fertigspritze(n)
Galenic form
Injektionslösung
Galenic group
Injektion/Infusion

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
15/07/2026
Summary of Product Characteristics
Français
15/07/2026
Summary of Product Characteristics
Italien
15/07/2026

Detailed composition

Substance Quantity Type Category
afliberceptum
2.0 MG Substance Wirkstoff (Principe actif)
histidinum
- Substance HNIDK
histidini hydrochloridum monohydricum
- Substance HNIDK
trehalosum dihydricum
- Substance HNIDK
poloxamerum 188
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK

Reimbursement information

Public price
CHF 478.45
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/08/2026

Authorization holder

Advanz Pharma Specialty Medicine

8048 Zürich

Authorization information

Swissmedic authorization number
70617
Drug name
Mynzepli, Injektionslösung in einer Fertigspritze
Galenic form
INLFS
ATC Code
S01LA05
Authorization status
Z
Dispensing category
B
First authorization
13/05/2026
Authorization expiration date
12/05/2031
IT Number
11.99.0.
Domain
Human medicine
Field of application
Exsudative (feuchte) altersbezogene Makuladegeneration (AMD). Makulaödem infolge eines retinalen Zentralvenenverschlusses (CRVO) und retinalen Venenastverschlusses (BRVO), diabetisches Makulaödem (DME), Behandlung von subfovealen und juxtafovealen choroidalen Neovaskularisationen infolge einer pathologischen Myopie (mCNV).

Package details

Description (FR)
MYNZEPLI 40 mg/ml sol inj ser prérempl 2 mg 1 pce
Description (DE)
MYNZEPLI 40 mg/ml Inj Lös Fertigspr 2 mg 1 Stk
Market launch
01/08/2026
Narcotic (BTM)
No
Buy us a coffee Explore the data